Anixa Biosciences (NASDAQ:ANIX) Releases Earnings Results, Beats Estimates By $0.02 EPS

Anixa Biosciences (NASDAQ:ANIX) issued its quarterly earnings data on Friday. The company reported ($0.09) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.11) by $0.02, Zacks reports.

Anixa Biosciences Stock Performance

Shares of ANIX opened at $2.25 on Friday. Anixa Biosciences has a 1 year low of $2.14 and a 1 year high of $5.13. The company’s 50 day simple moving average is $2.94 and its 200 day simple moving average is $3.02. The company has a market capitalization of $72.40 million, a price-to-earnings ratio of -5.77 and a beta of 0.90.

Analyst Ratings Changes

ANIX has been the subject of several recent research reports. HC Wainwright reissued a “buy” rating and set a $7.00 price target on shares of Anixa Biosciences in a research report on Tuesday, November 19th. D. Boral Capital reaffirmed a “buy” rating and set a $10.00 price objective on shares of Anixa Biosciences in a research note on Tuesday, November 19th.

Anixa Biosciences Company Profile

Anixa Biosciences, Inc, a biotechnology company, develops therapies and vaccines focusing on critical unmet needs in oncology and infectious diseases. The company's therapeutics programs include the development of a chimeric endocrine receptor T-cell therapy, a novel form of chimeric antigen receptor T-cell (CAR-T) technology focusing on the treatment of ovarian cancer.